Results 1 - 10 of 13 : 1 2 Next
Biomarin soars a day later than everyone else.
A Top BioMarin Drug Heads Overseas
BioMarin's Kuvan is tentatively given the thumbs up in Europe.
Regeneron's Results Clearing Up
The drugmaker presents new data on a compelling candidate.
BioMarin's New Drugs Mostly Hit Their Targets
When minor changes in guidance cause increased worries.
These stocks have been the subject of negative sentiment, but that hasn't stopped them from outperforming over the past month.
So far in 2008, the agency's given more drugs a thumbs-up.
Regeneron's Orphan Charms the FDA
The drug to treat a rare disease gets the OK.
Surprising Low-Rated Stocks the Leaders Love
See what the best CAPS players recommend now.
Regeneron Sees Positive Phase 2 Data
Data from macular degeneration drug trial looks good.
This Just In: Upgrades and Downgrades
The Street's smilin' at Mylan.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK